Insulet (PODD)
NASDAQ: PODD · Medical Devices · Acton, MA
Our rating: Positive
Positive reaffirmed at $156.12, moderate conviction, November 5, 2026.
Breaks if: The Positive call is wrong if revenue growth in either of the next two quarterly filings comes in below 18% year-over-year — that would signal the 30%-plus run rate is breaking down structurally rather than moderating gradually. It also turns Cautious if reported net margin falls below 7% over the same two-quarter window, implying operating leverage is running in reverse at scale. Neither condition is met today.
Key figures
| Market value | $9.2B |
|---|---|
| Revenue, last 12 months | $3.2B |
| Net income, last 12 months | $429M |
| Free cash flow, last 12 months | $260M |
| Price to earnings | 21.5× |
| Free cash flow yield | 2.8% |
| Dividend yield | 0.0% |
| Operating margin | 18.4% |
| Return on equity | 28.9% |
| Beta to the S&P 500 | 0.69 |
| Volatility, annualized | 41.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $842M | 19.2% | $2.03 | $66M |
| June 30, 2026 | $802M | 23.5% | $1.37 | $56M |
| March 31, 2026 | $762M | 33.9% | $1.30 | $90M |
| December 31, 2025 | $784M | 31.2% | $1.43 | $48M |
| September 30, 2025 | $706M | 29.9% | $1.24 | $100M |
| June 30, 2025 | $649M | 32.9% | $0.32 | $178M |
| March 31, 2025 | $569M | 28.8% | $0.50 | $52M |
| December 31, 2024 | $598M | 17.2% | $1.38 | $94M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.99B: Claude 22%, Gemini 45%, Mistral 35%
- Diluted earnings per share are at least $1.43: Claude 78%, Gemini 90%, Mistral 70%
- Free cash flow for the quarter is at least $0.05B: Claude 80%, Gemini 95%, Mistral 85%
12 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.